Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.45 |
| ▸ | RHOC | P08134 | 2/20 | 0.45 |
| ▸ | RHOA | P61586 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | CETP | P11597 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256292 | 0.95 | TGFBR1 (0.47) | HPGDKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2257314 | 0.94 | TGFBR1 (0.47) | KDM4EALDH1A1TGFBR1RHOCRHOA | |
| SCHEMBL2257201 | 0.93 | TGFBR1 (0.45) | HPGDKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2263535 | 0.93 | KCNJ5 (0.48) | KDM4EALDH1A1TGFBR1RHOCRHOA | |
| SCHEMBL2259123 | 0.93 | KDM4E (0.47) | HPGDKDM4EALDH1A1TGFBR1CNR1 | |
| SCHEMBL2259102 | 0.92 | TGFBR1 (0.47) | HPGDKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2258261 | 0.92 | KDM4E (0.47) | HPGDKDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2258121 | 0.92 | RXRA (0.46) | KDM4EALDH1A1TGFBR1CNR1SMN1; SMN2 | |
| SCHEMBL2260513 | 0.91 | TGFBR1 (0.44) | KDM4EALDH1A1TGFBR1KMT2A | |
| SCHEMBL2258132 | 0.91 | NPC1 (0.45) | KDM4EALDH1A1TGFBR1ORAI1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | HPGD 866/4885KDM4E 2153/4885ALDH1A1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.